Trevi Therapeutics Statistics
Total Valuation
TRVI has a market cap or net worth of $681.69 million. The enterprise value is $579.39 million.
Important Dates
The last earnings date was Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TRVI has 101.74 million shares outstanding. The number of shares has increased by 7.29% in one year.
| Current Share Class | 101.74M |
| Shares Outstanding | 101.74M |
| Shares Change (YoY) | +7.29% |
| Shares Change (QoQ) | +10.94% |
| Owned by Insiders (%) | 15.78% |
| Owned by Institutions (%) | 58.33% |
| Float | 63.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.73 |
| P/TBV Ratio | 6.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.38, with a Debt / Equity ratio of 0.01.
| Current Ratio | 15.38 |
| Quick Ratio | 15.11 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17,029.33 |
Financial Efficiency
Return on equity (ROE) is -55.12% and return on invested capital (ROIC) is -36.70%.
| Return on Equity (ROE) | -55.12% |
| Return on Assets (ROA) | -34.41% |
| Return on Invested Capital (ROIC) | -36.70% |
| Return on Capital Employed (ROCE) | -51.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.82M |
| Employee Count | 26 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -33,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +145.42% in the last 52 weeks. The beta is 0.62, so TRVI's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +145.42% |
| 50-Day Moving Average | 6.13 |
| 200-Day Moving Average | 4.08 |
| Relative Strength Index (RSI) | 58.13 |
| Average Volume (20 Days) | 1,211,808 |
Short Selling Information
The latest short interest is 6.95 million, so 6.83% of the outstanding shares have been sold short.
| Short Interest | 6.95M |
| Short Previous Month | 5.91M |
| Short % of Shares Out | 6.83% |
| Short % of Float | 10.92% |
| Short Ratio (days to cover) | 4.29 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -51.09M |
| Pretax Income | -38.78M |
| Net Income | -47.35M |
| EBITDA | -50.94M |
| EBIT | -51.09M |
| Earnings Per Share (EPS) | -$0.44 |
Full Income StatementBalance Sheet
The company has $103.26 million in cash and $957,000 in debt, giving a net cash position of $102.30 million or $1.01 per share.
| Cash & Cash Equivalents | 103.26M |
| Total Debt | 957,000 |
| Net Cash | 102.30M |
| Net Cash Per Share | $1.01 |
| Equity (Book Value) | 99.46M |
| Book Value Per Share | 1.00 |
| Working Capital | 98.76M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$41.27 million and capital expenditures -$35,000, giving a free cash flow of -$41.30 million.
| Operating Cash Flow | -41.27M |
| Capital Expenditures | -35,000 |
| Free Cash Flow | -41.30M |
| FCF Per Share | -$0.41 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |